Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RT001 Botulinum toxin type A · 1 trial · 3 indications
The number of subjects who show improvement based on the investigator global assessment
| Arm | Type | Description |
|---|---|---|
| RT001 Botulinum toxin Type A (Dose A) | EXPERIMENTAL | RT001 (Botulinum toxin Type A) |
| RT001 Botulinum toxin type A (Dose B) | EXPERIMENTAL | RT001 (Botulinum Toxin Type A) |
| Dose C | OTHER | Vehicle Control |
| Dose D | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| RT001 Botulinum toxin type A (Dose A) | DRUG | RT001 Botulinum Toxin Type A (Dose A) |
| RT001 Botulinum Toxin Type A (Dose B) | DRUG | RT001 Botulinum Toxin Type A (Dose B) |
| Vehicle | OTHER | Vehicle Control |
| Placebo | DRUG | Placebo Comparator |
Inclusion Criteria: * Written informed consent including authorization to release health information * Female or male, 18 to 65 years of age and in good general health * Willing and able to follow study instructions and likely to complete all study requirements * Moderate to severe lateral canthal ...
RT001 Botulinum toxin type A is used for the treatment of moderate to severe lateral canthal lines, commonly known as crow's feet, in adults. It is a botulinum toxin type A formulation being developed for dermatological use to reduce facial wrinkles in this specific area.
RT001 Botulinum toxin type A targets the neuromuscular junction by inhibiting the release of acetylcholine, which temporarily paralyzes the underlying muscles responsible for dynamic wrinkles. This mechanism reduces the appearance of lateral canthal lines, or crow's feet, by relaxing the muscles around the eyes.
RT001 Botulinum toxin type A is being developed by Revance Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RVNC. The company is focused on developing innovative aesthetic and therapeutic products.
RT001 Botulinum toxin type A is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial has been completed to evaluate its efficacy and safety for the treatment of lateral canthal lines.
RT001 Botulinum toxin type A has one completed Phase 2 clinical trial, identified as NCT01124552. This was a 4-arm, randomized, double-blind, placebo-controlled study involving 180 participants in the United States, evaluating the treatment of moderate to severe lateral canthal lines in adults.
RT001 Botulinum toxin type A is a specific formulation of botulinum toxin type A developed by Revance Therapeutics. While it belongs to the same class as other botulinum toxin type A products, it is a distinct investigational product with its own clinical development program.